Holen Sie sich die Stockscreener-App
62.34
0.05%
-0.03
Handel nachbörslich:
62.20
-0.14
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$62.37
Offen:
$62.37
24-Stunden-Volumen:
17.62M
Relative Volume:
1.24
Marktkapitalisierung:
$126.95B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
18.02
EPS:
3.4587
Netto-Cashflow:
$12.85B
1W Leistung:
+1.78%
1M Leistung:
+11.54%
6M Leistung:
+31.49%
1J Leistung:
+4.56%
1-Tages-Spanne:
$61.98
$62.89
1-Wochen-Bereich:
$60.65
$62.89
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
62.34 | 127.01B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,017.97 | 992.40B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.56 | 598.69B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
234.26 | 410.36B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
166.87 | 321.75B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
203.73 | 323.26B | 58.80B | 10.24B | 8.98B | 3.2788 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Mitsubishi UFJ Asset Management Co. Ltd. Has $204.06 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments - Kalkine Media
Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients - Benzinga
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer - BioPharma Dive
Bristol Myers: Biokin reports ‘positive’ results from Phase 3 study of iza-bren - TipRanks
Bristol Myers Squibb (BMY) Achieves Breakthrough in Breast Cance - GuruFocus
Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce Biotech
Bristol Myers Squibb's Antibody Drug Achieves Success in China Trial - Intellectia AI
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug - Seeking Alpha
Primecap Management Co. CA Sells 850,330 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer - Business Wire
RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth - Finviz
Buybacks Report: Why is Bristol Myers Squibb Company Equity Right stock going upJuly 2025 Selloffs & Daily Profit Maximizing Tips - baoquankhu1.vn
2nd Circ. Skeptical Of Expanding Collectives' Borders - Law360
Why Bristol Myers Squibb Stock Topped the Market Today - AOL.com
Bristol-Myers Squibb Advances Pediatric Lymphoma Combo, Signaling Quiet Upside for BMY Investors - TipRanks
5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever - 24/7 Wall St.
Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal - San Diego Business Journal
RBC initiates Bristol-Myers Squibb stock at Sector Perform, $60 target - Investing.com
3 Reasons to Avoid BMY and 1 Stock to Buy Instead - Finviz
FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review - Finviz
Biopharma bites: Layoffs at BMS, Generate's IPO plans, Fortress's voucher sale…and more - FirstWord Pharma
FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation - Yahoo Finance UK
Bristol Myers Squibb discloses 247 more layoffs in NJ (updated) - NJBIZ
Bristol-Myers Touts Promising Data From Blood Disorder Study - Bitget
Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential - Finviz
Bristol-Myers Squibb’s New Rheumatoid Arthritis Trial: What Early Pipeline Moves Mean for BMY Investors - TipRanks
Bristol-Myers Squibb (BMY) Gets Price Target Raise by Piper Sand - GuruFocus
Bristol Myers Squibb (BMY) Reports Positive Phase 2 Trial Results for Reblozyl - GuruFocus
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 - Investing.com
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 By Investing.com - Investing.com India
Bristol Myers Squibb’s Reblozyl meets trial goals for alpha-thalassemia - Investing.com
BMY: Promising Phase 2 Results for Reblozyl in Alpha-Thalassemia Study - GuruFocus
Large-Cap Stock Analysis 2026: Vertiv, HCA Healthcare, Bristol-Myers SquibbNews and Statistics - IndexBox
China Universal Asset Management Co. Ltd. Purchases New Stake in Bristol Myers Squibb Company $BMY - Defense World
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? - The Motley Fool
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? - The Globe and Mail
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Barclays initiates Bristol-Myers Squibb stock coverage at overweight - Investing.com
Barclays initiates Bristol-Myers Squibb stock coverage at overweight By Investing.com - Investing.com India
ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance UK
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Finviz
Bristol Myers Squibb (NYSE:BMY) Delivers Stability While S&P 500 Stays Volatile - Kalkine Media
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma - Finviz
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Yahoo Finance
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):